Baidu
map

两票制文件即将发布!29省推进一览

2016-10-23 佚名 易联招采网

有关两票制文件的专家会签本周已经结束,出台在即!与此同步的是,29省进展不一,请看整理汇总:自年初《国务院办公厅关于印发深化医药卫生体制改革2016年重点工作任务的通知》(国办发〔2016〕26号)要求“优化药品购销秩序,压缩流通环节,综合医改试点省份要在全省范围内推行两票制,积极鼓励公立医院综合改革试点城市推行两票制”以来,各省积极筹备两票制具体工作。国务院明确,医改试点省份要在全范围内推广

有关两票制文件的专家会签本周已经结束,出台在即!与此同步的是,29省进展不一,请看整理汇总:

自年初《国务院办公厅关于印发深化医药卫生体制改革2016年重点工作任务的通知》(国办发〔2016〕26号)要求“优化药品购销秩序,压缩流通环节,综合医改试点省份要在全省范围内推行两票制,积极鼓励公立医院综合改革试点城市推行两票制”以来,各省积极筹备两票制具体工作。

国务院明确,医改试点省份要在全范围内推广两票制,鼓励一票制,医院和药品生产企业的直接结算货款,药企和配送企业计算配送费用。今年新增了7个医改试点省,加上此前4个,国家医改试点省达到了11个,即安徽、福建、江苏、青海、陕西省、上海市、浙江省、四川省、湖南、重庆、宁夏等。

目前现状

1、已经推行两票制的省份

福建:福建是全国唯一一个真正实施两票制的省份,从2012年7标开始,全省贯彻落实,基本上没有死角。并在推进过程中通过行政手段将基药配送集中到10个配送商,之后,又将非基药也进行了进一步整合,归拢至11家配送商业。两票制+配送商业整合,改变了该省医药流通的市场生态。全国各大药品厂家,也通过了福建市场的洗礼,逐渐适应市场的需要,尝试‘高开’与底价并行的开票方式。

2、明确了执行时间点的省份

安徽:安徽作为医改标兵,一直走在各省前沿,前段时间,安徽已经下发推行“两票制”实施意见,明确了具体要求和规定,要求自2016年11月1日起执行两票制。

陕西:据传早在4月15日陕西省卫计委邀请了4家生产企业与4家配送企业召开了座谈会,该会重点围绕“两票制”对行业的影响、具体推行举措等内容。果然,在10月初,陕西发布了《关于深化药品耗材供应保障体系改革的通知》,要求制定“两票制”的具体实施意见,在2017年1月起启动实施。

广东:在今年9月发布的《广东省促进医药产业健康发展实施方案》中要求:健全政府采购机制。优化药品购销秩序,压缩流通环节,自2017年起,稳步推行生产企业到流通企业、流通企业到医疗机构“两票制”和药品耗材采购院长负责制。

3、明确要推行两票制的省份

目前除了广西、北京、黑龙江暂未有任何信息透露出要进行两票制的意思,其它省份都或多或少已经透露要推行两票制。

后续预测

预测1、可能会较先实施的省份

医改试点省份:既然是医改试点省份,而且又是国家全力推行的,无论是已经明确执行时间的安徽、陕西还是本来就已经执行两票制的福建,都是医改试点省份,因此,医改试点省份肯定是先行者,随着安徽两票制具体文件的出台,其它省份也会陆续跟进。如江苏内部已经讨论过。

作为医改试点省份之一的江苏,在国务院公布《2016年医改重点工作任务》次日,便率先发文推进“两票制”落地。从业内流传的文件来看,大家是否注意到,在朋友圈疯传的江苏的“红头文件”中,发文单位是江苏省食药监局药品流通监管处。但是有人疑问药品集中采购的主管部门不是卫计委么?为啥是药监部门首先积极响应政策?

有业内人士表示,由于“两票制”能更好的应对电子监管码废除之后的药品溯源体系建设,药监部门积极推进“两票制”,也是顺应药监部门的监管趋势。


(注:非官方资料)

湖南最新动态明确要政策落地:4月21日,省委深改组第十七次次会议审议通过了《湖南省深化医药卫生体制综合改革试点方案》,标志着湖南省即将进入“两票制时代”。
2016年9月份的湖南卫生计生简报[2016]第15期要求在政府相关部门的组织实施下,把药物流通“两票制”在湖南落地,让药品从企业到医院走最短的流通路线。显然湖南也准备加快两票制进程。

浙江新平台条件已成熟:
浙江的“三流合一”平台已经正式上线运行,从运行情况来看,各项工作开展顺利。新平台不仅能满足两票制,甚至能满足一票制,因此,浙江在条件成熟的情况下,可能会较快落实具体的两票制政策。

其他省份如河北先期也进行过讨论:
河北省确定了27家县级公立医院作为试点,借鉴三明市医改经验,以药价作为切入点,将试点县将加入三明药品耗材限价联盟,推行‘一品两规’‘两票制’和‘药品采购院长负责制’,建立健全与当地医改相配套的药品耗材集中采购新机制,采取多种措施从‘根’上解决药价虚高问题。从河北推行的力度看,不仅仅是两票制一项措施,而是全方位学习三明,堪称‘重度介入’。


(注非官方资料)

预测2、部分省份的公立医院改革试点城市会先推行
 
如海南、吉林、甘肃、山西、辽宁、江西、河南、云南、山东、内蒙古都提到要在公立医院改革试点城市推行两票制。具体情况如下所列:
《海南省深化医药卫生体制改革2016年重点工作任务》:优化药品购销秩序,压缩流通环节,鼓励公立医院综合改革市县和试点城市推行“两票制”

吉林《关于印发2016年纠正医药购销和医疗服务中不正之风专项治理工作要点的通知》:在综合医改试点省和城市公立医院综合改革试点地区的药品、耗材采购中实行“两票制”。

《甘肃省深化医药卫生体制改革2016年重点工作任务》:鼓励庆阳、白银、酒泉3个公立医院改革试点城市继续开展药品带量采购工作,推行“两票制”。

《山西省深化医药卫生体制改革2016年重点工作任务》:积极鼓励公立医院综合改革试点城市推行“两票制”。

《辽宁省深化医药卫生体制改革近期重点工作任务》:积极鼓励公立医院综合改革试点城市推行“两票制”。

江西《2016年全省深化医药卫生体制改革重点工作任务》:积极鼓励公立医院综合改革试点城市推行“两票制”。

《河南省深化医药卫生体制改革2016年重点工作任务》:,鼓励公立医院综合改革试点城市推行“两票制”。

《云南省深化医药卫生体制改革2016年重点工作任务》: 积极鼓励公立医院综合改革试点城市推行“两票制”。

《山东省深化医药卫生体制改革2016年重点工作任务》: 鼓励潍坊、东营、威海等国家联系试点城市推行“两票制”。

《内蒙古自治区深化医药卫生体制改革2016年重点工作任务》: 鼓励公立医院综合改革试点城市推行“两票制”

预测3、2017年是两票制落实关键年份
 
目前已经确定时间点的几个省份,广东和陕西都定在2017年,安徽是今年11月就开始执行。从各省份时间进展来看,我们认为2017年可能是各省两票制落实的关键时间,各省具体政策文件、落实详细工作安排应该会集中在2017年展开。

预测4、部分医改试点省份难以全面推行
 
《四川省深化医药卫生体制综合改革试点方案》:深化药品流通领域改革,压缩中间流通环节,在条件成熟的地方推行“两票制”。打破了大家普遍认为的综合医改试点省份将全面推行两票制的观点,是第一个明确提出无法做到全面推行两票制的综合医改试点省份。

四川作为中国西部的人口大省,地域广阔、地形复杂,很多偏远地区的公立医院难以做到在两票内将药品配送到达,完全执行两票制可能导致这些偏远地区的公立医院无药可用,因此才会有“在条件成熟的地方推行“两票制””的说法。

西部的医改试点省份中与四川有相同情况的还有陕西、青海,目前陕西已经要求制定“两票制”的具体实施意见,在2017年1月起启动实施,但具体会怎么实施还未明确。而青海还未有任何消息,可能也难以做到全面推行两票制。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1419496, encodeId=22451419496b0, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Tue Oct 25 07:11:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150833, encodeId=e87415083334, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:25 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150723, encodeId=ad6b150e23e1, content=谢谢谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Oct 24 00:24:51 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150642, encodeId=920115064298, content=这个政策可以的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Sun Oct 23 17:01:05 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150631, encodeId=66dd150631d5, content=很有用处,了解了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:18:13 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150629, encodeId=63851506291d, content=视频很好,值得反复学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:50 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150628, encodeId=1ced15062860, content=学习到了很多,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:43 CST 2016, time=2016-10-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1419496, encodeId=22451419496b0, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Tue Oct 25 07:11:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150833, encodeId=e87415083334, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:25 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150723, encodeId=ad6b150e23e1, content=谢谢谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Oct 24 00:24:51 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150642, encodeId=920115064298, content=这个政策可以的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Sun Oct 23 17:01:05 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150631, encodeId=66dd150631d5, content=很有用处,了解了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:18:13 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150629, encodeId=63851506291d, content=视频很好,值得反复学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:50 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150628, encodeId=1ced15062860, content=学习到了很多,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:43 CST 2016, time=2016-10-23, status=1, ipAttribution=)]
    2016-10-24 xyfg98

    谢谢分享!学习了。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1419496, encodeId=22451419496b0, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Tue Oct 25 07:11:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150833, encodeId=e87415083334, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:25 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150723, encodeId=ad6b150e23e1, content=谢谢谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Oct 24 00:24:51 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150642, encodeId=920115064298, content=这个政策可以的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Sun Oct 23 17:01:05 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150631, encodeId=66dd150631d5, content=很有用处,了解了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:18:13 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150629, encodeId=63851506291d, content=视频很好,值得反复学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:50 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150628, encodeId=1ced15062860, content=学习到了很多,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:43 CST 2016, time=2016-10-23, status=1, ipAttribution=)]
    2016-10-24 1e0ece0dm09(暂无匿称)

    谢谢谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1419496, encodeId=22451419496b0, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Tue Oct 25 07:11:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150833, encodeId=e87415083334, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:25 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150723, encodeId=ad6b150e23e1, content=谢谢谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Oct 24 00:24:51 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150642, encodeId=920115064298, content=这个政策可以的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Sun Oct 23 17:01:05 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150631, encodeId=66dd150631d5, content=很有用处,了解了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:18:13 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150629, encodeId=63851506291d, content=视频很好,值得反复学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:50 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150628, encodeId=1ced15062860, content=学习到了很多,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:43 CST 2016, time=2016-10-23, status=1, ipAttribution=)]
    2016-10-23 Carlos007

    这个政策可以的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1419496, encodeId=22451419496b0, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Tue Oct 25 07:11:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150833, encodeId=e87415083334, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:25 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150723, encodeId=ad6b150e23e1, content=谢谢谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Oct 24 00:24:51 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150642, encodeId=920115064298, content=这个政策可以的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Sun Oct 23 17:01:05 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150631, encodeId=66dd150631d5, content=很有用处,了解了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:18:13 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150629, encodeId=63851506291d, content=视频很好,值得反复学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:50 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150628, encodeId=1ced15062860, content=学习到了很多,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:43 CST 2016, time=2016-10-23, status=1, ipAttribution=)]
    2016-10-23 1e0ba702m86(暂无匿称)

    很有用处,了解了不少

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1419496, encodeId=22451419496b0, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Tue Oct 25 07:11:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150833, encodeId=e87415083334, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:25 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150723, encodeId=ad6b150e23e1, content=谢谢谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Oct 24 00:24:51 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150642, encodeId=920115064298, content=这个政策可以的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Sun Oct 23 17:01:05 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150631, encodeId=66dd150631d5, content=很有用处,了解了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:18:13 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150629, encodeId=63851506291d, content=视频很好,值得反复学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:50 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150628, encodeId=1ced15062860, content=学习到了很多,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:43 CST 2016, time=2016-10-23, status=1, ipAttribution=)]
    2016-10-23 1e0ba702m86(暂无匿称)

    视频很好,值得反复学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1419496, encodeId=22451419496b0, content=<a href='/topic/show?id=447d2109ee4' target=_blank style='color:#2F92EE;'>#两票制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21097, encryptionId=447d2109ee4, topicName=两票制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1103505700, createdName=天堂的云, createdTime=Tue Oct 25 07:11:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150833, encodeId=e87415083334, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:25 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150723, encodeId=ad6b150e23e1, content=谢谢谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Mon Oct 24 00:24:51 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150642, encodeId=920115064298, content=这个政策可以的, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Sun Oct 23 17:01:05 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150631, encodeId=66dd150631d5, content=很有用处,了解了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:18:13 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150629, encodeId=63851506291d, content=视频很好,值得反复学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:50 CST 2016, time=2016-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150628, encodeId=1ced15062860, content=学习到了很多,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Oct 23 16:16:43 CST 2016, time=2016-10-23, status=1, ipAttribution=)]
    2016-10-23 1e0ba702m86(暂无匿称)

    学习到了很多,受益匪浅

    0

相关资讯

广东明确2017年全面执行两票制!

近日,广东省人民政府办公厅印发《关于促进医药产业健康发展实施方案》。文件中除了明确到2020年,全省医药产业产值达到4000亿元等目标,还对两票制也提出了部署:自2017年起,稳步推行生产企业到流通企业、流通企业到医疗机构“两票制”和药品耗材采购院长负责制。这是广东首次在正式文件中明确了两票制的推行时间。明年起,广东全面执行两票制两票制的概念首先在广东出现,但是最终却因反对作罢。2006年,医

两票制真落地了,安徽下月执行!

昨日(10月8日),国庆节假期回来的第一个工作日,安徽省食药监局给我们带来重磅通知,印发了《安徽省公立医疗机构药品采购推行“两票制”实施意见》,并明确自2016年11月1日起执行。两票制落地,真的来了!今年4月26日,国务院正式发文,明确医改试点省份推广“两票制”,业界一片哗然的同时,大家最关心的是政策什么时候开始落实。按规定,今年之内“两票制”在国家医改试点省份必须落地。如今,安徽的两票制政

两票制落地:11省政策大汇总,1011试点县名单

导语:你了解抑郁症患者眼中的世界吗?

营改增+两票制,找票难!提现难!活下去更难!求生存求活路!

自4月份以来,医药行业欲执行两票制政策万众瞩目,其中最为核心的是两票制如何界定。政策暂未出台,行业亟待明确,近日据权威媒体披露,两票制政策或有重大调整,两票制的界定由原来的“每个独立法人企业开出的发票为一票”,或调整为“药企或科工贸一体化的集团型企业设立的仅销售本企业(集团)药品的全资或控股商业公司、境外药品总代理可视同生产企业,但仅限一家商业公司、一家国内总代理,且加价须控制在一定范围内”,还有

两票制后,医药市场发生了8件事!

导语:两票制后医药行业将受到前所未有的挑战,8个真实案例揭示市场一线正发生着什么 两票制执行,医药行业将受到前所未有的挑战,市场一线正发生着什么?下面是医药人Fuktak给赛柏蓝提供的市场一线的8个真实案例: 1.某地区盛传涨价,终端客户大量囤货,业务员无货可卖。 2.某企业联合区域商业公司开订货会,场场爆满,销售没有任何影响。 3.某地区某企业业务员被

两票制和配送:打破医用耗材市场格局

前言:今年4月26日,国务院正式发文,明确医改试点省份推广“两票制”,按国务院26号文的规定,今年之内“两票制”在国家医改试点省份必须落地。国家的决心之大意味着两票制一定会执行,只不过各省执行到位的时间有所不同而已,医药和医疗器械行业各方人士一片哗然,倍感生存的压力。 何为两票制:生产企业到流通企业开一次发票,流通企业到医疗机构开一次发票。全国总代及进口商算第一票,托管商业进货不算一票,母公司给

Baidu
map
Baidu
map
Baidu
map